Belantamab mafodotin
DrugWikipedia
5
MENTIONS
4
EPISODES
4
PODCASTS
Search complete. 5 mentions across 4 episodes found for "Belantamab mafodotin".
Aug 24, 2026
Joseph MikhaelGUEST
The attitude is use the best we can up front, whether it's gonna be CAR T, a bispecific, a Cel Mod, or antibody drug conjugate.
Joseph MikhaelGUEST
I still think belantamab mafodotin has a significant role as well.
Joseph MikhaelGUEST
So I really do think that we can use it earlier on, especially now as we've reduced the toxicity with important holding and bridging therapy, as we've come to understand it a little bit more, and of course with new CAR Ts coming.
Joseph MikhaelGUEST
So I do think that in general, I'm favoring bringing CAR T as early as it is available for an individual patient, not only 'cause of its e- efficacy and its now better controlled safety.
speaker_0HOST
This shift in FDA leadership is expected to influence the speed and efficiency with which new treatments reach patients, highlighting the agency's evolving role in balancing innovation with safety.
speaker_0HOST
In Singapore, GSK's Blenrep has received approval for use in combination therapies targeting relapsed or refractory multiple myeloma.
speaker_0HOST
This antibody drug conjugate specifically targets the BCMA protein on myeloma cells, offering new hope for patients who have exhausted conventional treatment options.
speaker_0HOST
The approval exemplifies ongoing advancements in targeted therapies aimed at improving outcomes for complex cancers.
María-Victoria MateosGUEST
So I think that there is another possibility for combining cell modes within the T-cell redirecting therapy, like bispecific monoclonal antibodies.
María-Victoria MateosGUEST
And as we've previously discussed, I think that the cell modes are going to be very valid in order to sequence CAR T-cell therapy, bispecific monoclonal antibodies, and why not to incorporate also Belantamav and Mafodotin, that it will be another potential combination.
María-Victoria MateosGUEST
Belantamav in combination with either a iverdomide.
Meletios-Athanasios (Thanos) C. DimopoulosGUEST
Absolutely.
Robert Z OrlowskiGUEST
And I think the activity is such that it's definitely worth the look for all the reasons that we've talked about.
Neil LoveHOST
So, Amrita, you were saying before we started here, you weren't sure where Belantamab was going to fit in terms of first-line therapy.
Neil LoveHOST
And I'm just a real simple person.
Neil LoveHOST
I look at that curve compared to Daira, and I go, well, why wouldn't it be in first-line therapy? You're there in SWOG trying to figure out what to do next.
Neil LoveHOST
What do you think about these trials looking at Belantamab up front?
Amrita KrishnanGUEST
Well, I mean, there was the DREAM-9 trial that got updated at ASCO this year where they tried to mitigate some of that oculotox with different schedules and doses.
Amrita KrishnanGUEST
And so many doses, so many schedules.